Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 371

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 371
---
 of intangibles assets useful economic lives |                                  |
| Goodwill                                             | – Indefinite life                |
| IPRD                                                 | – In process, not yet amortising |
| IT and website costs                                 | – 4 years                        |

The useful economic
life of IPRD will be determined when the in-process research projects are completed.

Internally generated intangible assets (development costs)

Expenditure on the research
phase of an internal project is recognised as an expense in the period in which it is incurred. Development costs incurred on specific
projects are capitalised when all the following conditions are satisfied:

| · | completion of the asset is technically feasible so that it will be available for use or sale; |

| · | the Group intends to complete the asset and use or sell it; |

| · | the Group has the ability to use or sell the asset and the asset will generate probable future economic benefits (over and above cost); |

| · | there are adequate technical, financial and other resources to complete the development and to use or sell the asset; and |

| · | the expenditure attributable to the asset during its development can be measured reliably. |

All internal activities
related to the research and development of new projects are continuously monitored by the Directors. The Directors consider that the criteria
to capitalise development expenditure are not met for a product prior to that product receiving regulatory approval in at least one country.

Development expenditure
not satisfying the above criteria, and expenditure on the research phase of internal projects are included in research and development
costs recognised in the Consolidated Statement of Comprehensive Income as incurred. No projects have yet reached the point of capitalisation.

Impairment of non-financial assets

Assets that have an
indefinite useful life, for example goodwill, or intangible assets not ready for use, such as IPRD, are not subject to amortisation and
are tested annually for impairment. Assets that are subject to amortisation are reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset’s
carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell
and value in use. The reversal of any impairment charge is limited to the carrying amount of the asset that would have been determined
(net of amortisation or depreciation) had no impairment charge been recognised for the asset in prior periods.

For